| AKEBIA THERAPEUTICS |
| USA |
| Gesundheit |
| US00972D1054 / A1XF0S |
| AX9 (Frankfurt) / AKBA (NASDAQ) |
| FRA:AX9, ETR:AX9, AX9:GR, NASDAQ:AKBA |
| - |
| https://akebia.com/ |
|
Akebia Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for patients with kidney disease. It leverages its expertise in kidney diseas..
>Volltext.. |
| 274.37 Mio. EUR |
| 299.69 Mio. EUR |
| 203.3 Mio. EUR |
| 21.32 Mio. EUR |
| -4.6 Mio. EUR |
| -0.01 EUR |
| 186.17 Mio. EUR |
| 160.56 Mio. EUR |
| 58.52 Mio. EUR |
| 1.14 |
| 29.97% |
| 93.21% |
| - |
| - |
| - |
| AKEBIA |
| 09.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|